Bellemonde expands resi project near Bucharest
Romanian developer Bellemonde is set to expand its residential project in Pipera, near Bucharest, will take the total investment to around €70 million.
Romanian developer Bellemonde is set to expand its residential project in Pipera, near Bucharest, will take the total investment to around €70 million.
Located in Pipera, Bellemonde residential development is designed to offer a complete living experience, featuring expansive common areas and a low housing density.
Victor Terheș, Sales Director at Bellemonde, talked to Property Forum about the status of its €40 million residential investment in northern Bucharest and the growing demand for homes in this area in the long term.
The Bellemonde residential complex in Pipera, near Bucharest, is recording growth in sales for its villas and apartments.
The groundwork and all foundation excavation have already been completed for the Bellemonde project, which will benefit from a total investment exceeding €40 million.
The construction of the Bellemonde project will benefit from a total investment of over €40 million.
Romanian developer Bellemonde Developement has obtained €21 million in funding from Libra Internet Bank for a residential project in Pipera, near Bucharest.
The construction of the Bellemonde project is scheduled to begin in June and will benefit from a total investment of over €40 million.
The study reveals that 83% of Romanians have a plan for their upcoming vacation season. Only 6% do not intend to go on holiday, while 12% have yet to finalize their arrangements.
Travel tech company FlixBus is adding new international coach connections from Romania to Greece and bolstering existing routes to Bulgaria.
EDP, through its subsidiary EDP Renewables, has opened its largest solar park in Romania, located in Albina, taking its total solar and wind capacities in the country to 570 MW.
Dan Air, a private Romanian airline, inaugurated its regular flight service between Bucharest and Damascus on June 15.
Romanian patients wait, on average, 460 days to access innovative medicines, even after these therapies have been approved for reimbursement by the National Agency for Medicines and Medical Devices (ANMDM).